CareDx (CDNA) Set to Announce Earnings on Monday

CareDx (NASDAQ:CDNA) is scheduled to post its quarterly earnings results after the market closes on Monday, November 4th. Parties interested in participating in the company’s conference call can do so using this link.

CareDx (NASDAQ:CDNA) last announced its earnings results on Wednesday, July 31st. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.37. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. The business had revenue of $92.27 million for the quarter, compared to the consensus estimate of $67.20 million. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CareDx Price Performance

Shares of NASDAQ:CDNA opened at $22.64 on Friday. The company’s fifty day moving average price is $28.23 and its 200-day moving average price is $20.47. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -7.40 and a beta of 1.77. CareDx has a one year low of $5.89 and a one year high of $34.84.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Craig Hallum raised their price target on CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. HC Wainwright reissued a “neutral” rating on shares of CareDx in a report on Tuesday, October 22nd. StockNews.com raised CareDx from a “hold” rating to a “buy” rating in a research note on Thursday, October 17th. The Goldman Sachs Group lifted their price target on shares of CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Finally, Wells Fargo & Company initiated coverage on shares of CareDx in a research note on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 price objective for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $30.60.

Insider Activity at CareDx

In other news, Director Peter Maag sold 35,552 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $33.04, for a total transaction of $1,174,638.08. Following the completion of the sale, the director now directly owns 330,024 shares in the company, valued at approximately $10,903,992.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other CareDx news, insider Alexander L. Johnson sold 34,231 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $33.55, for a total value of $1,148,450.05. Following the completion of the transaction, the insider now directly owns 284,983 shares in the company, valued at approximately $9,561,179.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter Maag sold 35,552 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total transaction of $1,174,638.08. Following the completion of the sale, the director now owns 330,024 shares of the company’s stock, valued at $10,903,992.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 91,340 shares of company stock worth $3,025,415 in the last three months. 4.90% of the stock is owned by insiders.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.